#ICYMI at #AACR26: Y. Liang presented, “A novel DLL3 trispecific T cell engager antibody integrating the CD2/CD58 co-stimulatory pathway ...

Journal for ImmunoTherapy of Cancer· @jitcancer · X·2026-04-21 23:01· 2026-04-21Score60

Reading

Next-generation ADCs: payload innovation

Body

#ICYMI at #AACR26: Y. Liang presented, “A novel DLL3 trispecific T cell engager antibody integrating the CD2/CD58 co-stimulatory pathway demonstrates superior antitumor efficacy and balanced safety profile”. Find how trispecific T cell engager design is advancing the treatment of multiple myeloma in this cutting-edge #JITC study:
https://
jitc.bmj.com/content/14/2/e
013986
…

Heat 30 · 22 likes · 0 replies · 8 reposts

Conference abstracts

CT189NCT06885281matched by 代号 ZL-1310

Preliminary results from the phase 1b/2, open-label, multi-center study of ZL-1310, a DLL3-targeted ADC, in patients with neuroendocrine carcinomas and other selected solid tumors

Rohit Thummalapalli, Ming Lu, Alexander Spira, Amr Mohamed, Rahul Aggarwal, Yu Wang, Namrata Vijayvergia, Jordi Rodon, Andrew Scott Paulson, Pingkuan Zhang, Hui Yang, Yuan Xin, Jingmin Wen, Jie Chen

Read the abstract →

Source: Journal for ImmunoTherapy of Cancer · x.com